Literature DB >> 29032373

Differentiating Clostridium difficile Colitis from Clostridium difficile Colonization in Ulcerative Colitis: A Role for Procalcitonin.

Andrew R Reinink1, Julajak Limsrivilai, Bethany A Reutemann, Tristan Feierabend, Emily Briggs, Krishna Rao, Peter D R Higgins.   

Abstract

BACKGROUND/AIMS: Clostridium difficile infection (CDI) frequently complicates ulcerative colitis (UC) and can mimic disease flare. Differentiating UC flare from CDI remains a clinical challenge, particularly due to C. difficile colonization. Procalcitonin (PCT) is a serum biomarker for bacterial infections. We hypothesized that PCT would differentiate acute CDI from UC flare and C. difficile colonization.
METHODS: A single-center prospective cohort study was conducted from 2013 to 2016. All UC patients with a stool sample for C. difficile testing were eligible. A total of 117 patients were enrolled, while 20 were excluded. Chart review was performed.
RESULTS: Among 27 patients with CDI, median PCT was 60.7 (range 26-560.6) pg/mL, while among 90 patients without CDI, median PCT was 56.7 (range 25.1-2,252) pg/mL (p = 0.9). It was found that 14 patients with CDI responded completely to C. difficile treatment (CDI-R), while 8 patients did not and were diagnosed with UC flare (CDI-NR). For CDI-R, median PCT was 104.5 (range 26.3-560.6), compared to 40.3 (range 26.0-116.3) for CDI-NR (p = 0.036).
CONCLUSIONS: In UC patients presenting with diarrhea, serum PCT was not significantly higher in UC patients with positive C. difficile testing. However, PCT was significantly elevated in CDI-R versus CDI-NR, suggesting that PCT may have utility in making this discrimination.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  <italic>Clostridium difficile</italic>; Diagnosis; Procalcitonin; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 29032373      PMCID: PMC5899687          DOI: 10.1159/000481133

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  18 in total

1.  Serum procalcitonin levels in patients with myeloperoxidase-antineutrophil cytoplasmic antibodies-associated glomerulonephritis.

Authors:  Atsushi Komatsuda; Ayumi Omokawa; Takashi Fujiwara; Ryuta Sato; Masaru Togashi; Shin Okuyama; Ken-Ichi Sawada; Hideki Wakui
Journal:  Am J Med Sci       Date:  2012-02       Impact factor: 2.378

Review 2.  Markers of intestinal inflammation for the diagnosis of infectious gastroenteritis.

Authors:  Mark D Gonzalez; Craig B Wilen; Carey-Ann D Burnham
Journal:  Clin Lab Med       Date:  2015-03-18       Impact factor: 1.935

Review 3.  Diagnosis and treatment of Clostridium difficile in adults: a systematic review.

Authors:  Natasha Bagdasarian; Krishna Rao; Preeti N Malani
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

4.  Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea.

Authors:  George A Alba; Quynh A Truong; Hanna K Gaggin; Parul U Gandhi; Benedetta De Berardinis; Laura Magrini; Ednan K Bajwa; Salvatore Di Somma; James L Januzzi
Journal:  Am J Med       Date:  2015-07-11       Impact factor: 4.965

5.  Clinical significance of serum procalcitonin in patients with ulcerative colitis.

Authors:  Shigeo Koido; Toshifumi Ohkusa; Kazuki Takakura; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Mikio Kajihara; Kan Uchiyama; Hiroshi Arakawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

6.  The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission.

Authors:  Evelyn M Clayton; Mary C Rea; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Colin Hill; R Paul Ross
Journal:  Am J Gastroenterol       Date:  2009-03-24       Impact factor: 10.864

7.  Impact of Clostridium difficile on inflammatory bowel disease.

Authors:  Mazen Issa; Aravind Vijayapal; Mary Beth Graham; Dawn B Beaulieu; Mary F Otterson; Sarah Lundeen; Susan Skaros; Lydia R Weber; Richard A Komorowski; Josh F Knox; Jeanne Emmons; Jasmohan S Bajaj; David G Binion
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

8.  Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease.

Authors:  Suchitra K Hourigan; Sankar R Chirumamilla; Tracy Ross; Jonathan E Golub; Shervin Rabizadeh; Shehzad A Saeed; Charles O Elson; Ciaran P Kelly; Karen C Carroll; Maria Oliva-Hemker; Cynthia Sears
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

9.  Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.

Authors:  Nevin Oruç; Omer Ozütemiz; Necla Osmanoğlu; Tankut Ilter
Journal:  Turk J Gastroenterol       Date:  2009-03       Impact factor: 1.852

10.  Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.

Authors:  Klaus R Herrlinger; Rike Dittmann; Gunther Weitz; Jan Wehkamp; Diether Ludwig; Matthias Schwab; Eduard F Stange; Klaus Fellermann
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

View more
  2 in total

1.  Predictive Value of Procalcitonin in Acute Severe Ulcerative Colitis: Not Quite PerfeCT?

Authors:  Deok Whan Kim; Jeong Min An; Seong Pyo Hong; Ki Baik Hahm
Journal:  Dig Dis Sci       Date:  2019-11       Impact factor: 3.199

2.  Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.

Authors:  Sarah Rotondo-Trivette; Beibei Wang; Christopher Gayer; Riddhi Parsana; Yihui Luan; Fengzhu Sun; Sonia Michail
Journal:  Aliment Pharmacol Ther       Date:  2021-07-04       Impact factor: 9.524

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.